

DEC 10 2003 10:21AM

GW GLOBAL R&D IS

NO. 7801

RECEIVED
CENTRAL FAX CENTER

DEC 01 2003

OFFICIAL

FAX



GlaxoSmithKline

To Attn: Ex. Bernhardt, Art Unit 1624
.....
Company USPTO
.....
Fax 703-872-9306
.....
From Valerie L. Phillips
.....
Tel 919-483-8223 Fax 919-483-5730
.....
E-mail Vlp47157@gsk.com
.....
Date December 10, 2003 Pages including cover 10
Subject Copies of Response Sent on 8/11/03
.....

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 10/089,964
Filing Date: May 8, 2002
Applicant: Alvaro et al.
Title: Chemical Compounds

Pursuant to Examiner Bernhardt's request, transmittal herewith is a duplicate copy of the response and IDS filed 11 August 2003 together with the stamped postcard indicating receipt by the PTO. Please enter the response into the record.

Attached:
Certificate of transmission via facsimile
Copies: Postcard, IDS, PTO1449, Response to Restriction Requirement

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Response to Office Action is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on December 10, 2003.

Valerie L. Phillips

Valerie L. Phillips


The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

DOCKET No. PT 38001SW Date Mailed Aug. 8, 2003 Atty/Secy Lam/vp
MAILING: CERTIFICATE/ EXPRESS MAIL # _____
U.S. Serial No.: 10/089,964 Filing Date: May 8, 2003
Int'l App. No.: _____ Int'l Filing Date: _____

RECEIPT IS ACKNOWLEDGED FOR THE FOLLOWING:

- ☐ Appln Transmit +1 copy for: ☐ Provisional ☐ CIP
☐ Utility ☐ CONTIN ☐ DIV ☐ RCE ☐ TRADEMARK
☐ Specification _____ pgs ☐ Abstract _____ pgs
☐ Dcls _____ pgs ☐ Powers of Atty _____ pgs
☐ Drawings _____ Sheet(s)/Figs _____ to _____
☐ Assignment _____ pgs & Recordation Cover Sheet
☐ Transmit Ltr Nat'l Stage Entry +fee pg (3pgs)
☒ Information Disclosure Statement Suppl
☒ Form PTO-1449 1 pgs ☒ 8 References
☐ Amendment _____ 'esponse _____ pgs
☐ Petition for _____ month Extension of Time +1 copy
☐ Issue Fee Trans. (Part B) + 1 copy
☐ Copy of Notice to File Missing Parts
☐ Request for Nonpublication (1 pg)
☒ Authorization to Charge Dep. Acct. # 07-1392

- ☐ Copy of Notice to Comply
☐ Statement to Support Filing
☐ Diskette ☐ Sequence Lis
☐ Appeal Brief _____ pgs
☐ Petition _____ pgs
☐ Status Request
☐ 2nd Transmit for Nat'l Stage
☐ Resp. to Written Opinion
☐ Priority Doc # _____
☐ Notice of Appeal +fee
☒ Resp to Restrict Req 5 pgs
☐ Req to Correct Filing Recpt
☐ Copy of Filing Receipt
☐ Req for Cert of Correct _____ pgs



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Giuseppe ALVARO et al.

Serial No.: 10/089,964

Group Art Unit: 1614

Filed: May 8, 2002

Examiner: Emily Bernhardt

For: Chemical Compounds

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: 1-8
☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311, whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- D. ☒ Applicants hereby notify the Examiner of co-pending application serial no. 10/190,170, filed 3 July 2002, which is a continuation of the instant application and claims priority thereto:
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan


Registration No. 38,181

Date: 8 Aug 2003
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

Date: 8/8/03


Valerie L. Phillips

